يعرض 1 - 20 نتائج من 62 نتيجة بحث عن '"Finafloxacin"', وقت الاستعلام: 0.58s تنقيح النتائج
  1. 1
    Report

    المصدر: Determination of the Effect of Age and Gender on the Pharmacokinetics and Tolerability of a Single Dose of Finafloxacin-HCL in Healthy Volunteers

  2. 2
    Academic Journal

    المصدر: Antibiotics; Volume 12; Issue 7; Pages: 1096

    مصطلحات موضوعية: finafloxacin, in vitro activity, acidic pH, cystic fibrosis

    وصف الملف: application/pdf

    Relation: Novel Antimicrobial Agents; https://dx.doi.org/10.3390/antibiotics12071096

  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Report

    المصدر: A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation.
    Wagenlehner F, Nowicki M, Bentley C, Luckermann M, Wohlert S, Fischer C, Vente A, Naber K, Dalhoff A. Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02317-17. doi: 10.1128/AAC.02317-17. Print 2018 Apr.
    Taubert M, Luckermann M, Vente A, Dalhoff A, Fuhr U. Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02328-17. doi: 10.1128/AAC.02328-17. Print 2018 Apr.
    Vente A, Bentley C, Luckermann M, Tambyah P, Dalhoff A. Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02325-17. doi: 10.1128/AAC.02325-17. Print 2018 Apr.

  6. 6
    Academic Journal
  7. 7
    Report

    المصدر: An Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin After Single and Multiple Doses Administered Orally in Healthy Volunteers

  8. 8
    Report

    المصدر: Finafloxacin - A Double-blind, Placebo-controlled, Randomised, Dose-escalating, Crossover Study to Determine the Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects
    Taubert M, Chiesa J, Luckermann M, Fischer C, Dalhoff A, Fuhr U. Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e01122-17. doi: 10.1128/AAC.01122-17. Print 2017 Oct.

  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Report

    المساهمون: Prof. Dr. P. Malfertheiner, Director

    المصدر: An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter Pylori Infection

  12. 12
    Report

    المساهمون: Jasper Hein, MD, Prinzipal Investigator

    المصدر: A Double-Blind, Double-Dummy, Prospective, Randomized Multiple-Site Study of Oral Finafloxacin 300 mg b.i.d. Versus Oral Ciprofloxacin 250 mg b.i.d. in Patients With Lower Uncomplicated UTI (uUTI) With a Treatment Duration of 3 Days
    Vente A, Bentley C, Luckermann M, Tambyah P, Dalhoff A. Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02325-17. doi: 10.1128/AAC.02325-17. Print 2018 Apr.

  13. 13
    Report

    المساهمون: Michael Seiberling, MD, Prinzipal Study Investigator

    المصدر: A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single and Multiple Oral Doses of Finafloxacin Hydrochloride in Healthy Subjects and a Study of H. Pylori Treatment in Healthy Carriers

  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20